Company: INMB
Filing Date: 2025-10-03
Form Type: PRE 14A
Source: 0001213900-25-096059
Chunk: 18

Company: Inmune Bio, Inc.
Filing Date: 2025-10-03
Form: PRE 14A
Chunk 18
---
 1.6 | % |
| Kelly Ganjei(7)                                             |     |      348,376 |     |           1.3 | % |
| Marcia Allen(8)                                             |     |      222,583 |     |             * |   |
| All executive officers and directors as a group (7 persons) |     |    6,271,751 |     |          21.0 | % |

____________ *Less than one percent. (1)Consists of: (a) 1,554,106shares of common stock held by Mr. Tesi, (b) warrants to purchase 33,408shares of the Company’s common stock and (c) 1,174,549shares of common stock underlying options exercisable within 60 days of September 30, 2025. (2)David Moss was appointed Chief Executive Officer and director of the Company, effective August 13, 2025. Consists of: (a) 1,285,869 shares of common stock held by Mr. Moss, (b) warrants to purchase 25,718 shares of the Company’s common stock and (c) 1,141,667 shares of common stock underlying options exercisable within 60 days of September 30, 2025. (3)Consists of: (a) 1,510,806shares of common stock held by Mr. Lowdell, (b) warrants to purchase 14,423shares of the Company’s common stock and (c) 721,500shares of common stock underlying options exercisable within 60 days of September 30, 2025. (4)Cory Ellspermann was appointed Interim Chief Financial Officer effective August 4, 2025. Consists entirely of 156,250 shares of common stock underlying options exercisable within 60 days of September 30, 2025. (5)Consists of: (a) 82,187shares of common stock held by Mr. Schroeder, and (b) 330,583shares of common stock underlying options exercisable within 60 days of September 30, 2025. (6)Consists of: (a) 71,603shares of common stock held by Mr. Juda, and (b) warrants to purchase 29,603shares of the Company’s common stock and (c) 330,583shares of common stock underlying options exercisable within